Shorter, stronger radiation course works in noninvasive breast cancer

Share this article:

Accelerated external-beam radiotherapy is a viable treatment option for ductal carcinoma in situ (DCIS), suggest recent study results.

The current standard of treatment for DCIS, an early-stage and noninvasive form of breast cancer, is lumpectomy followed by 5 to 6 weeks of whole breast radiation, affirmed a statement from the American Society for Radiation Oncology (ASTRO) that accompanied the latest research findings. The use of an accelerated form of radiation that increases the strength of the dose per treatment throughout fewer treatment sessions has been well-established as effective against invasive breast cancers, but not against DCIS. 

Silvia C. Formenti, MD, a radiation oncologist at New York University School of Medicine, New York, New York, and colleagues conducted two consecutive clinical trials to determine whether accelerated radiation treatment would garner good results in women with DCIS. The team's findings were published in ASTRO's International Journal of Radiation Oncology, Biology, Physics (2012;83[2]:e159-e164).

The first trial used whole breast irradiation of 42 Gy (2.8 Gy in 15 fractions), and the second trial used whole breast irradiation of 40.5 Gy (2.7 Gy in 15 fractions) with an additional daily boost of 0.5 Gy to the surgical cavity. Between 2002 and 2009, 59 women were enrolled in the first protocol and 86 in the second after undergoing lumpectomy. Median age was 56 years, and 65% of the women were postmenopausal at the time of treatment.

At 5 years' median follow-up (range, 2.6 to 105.5 months), only six patients (4.1%) experienced ipsilateral breast recurrence. In three of those women, the cancer recurred at the original DCIS site. New contralateral breast cancers arose in three cases (one DCIS and two invasive carcinomas).

The recurrence rate was comparable to the recurrence rate of 5% to 10% recorded in randomized trials for patients receiving standard radiation.

Of 125 women providing cosmetic self-assessment at least 2 years after treatment, 91% reported good-to-excellent outcomes and 9% reported fair-to-poor outcomes. 

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Some aggressive cancers may respond to anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Single gene determines if rare lymphatic system cancer is aggressive

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that does not require extensive therapy.

More than 40 melanoma-specific genes determine disease aggressiveness

Researchers have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.